The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Real-world study of intranasal ketamine for use in patients with refractory chronic migraine
Open accessAbstract
Subanesthetic ketamine infusion has been used for managing refractory headache in inpatient or outpatient infusion settings. Intranasal (IN) ketamine may be an alternative option for outpatient care. We performed a retrospective study at a single tertiary headache center to assess the clinical effectiveness and tolerability of IN ketamine in patients with refractory chronic migraine (rCM). Candidates who received IN ketamine between January 2019 and February 2020 were screened through an electronic medical record query. Manual chart reviews and structured phone interviews were conducted upon obtaining informed consent. Among 242 subjects screened, 169 (age 44.3±13.8; female 79.9%) were interviewed. They reported 25.0±8.7 monthly headache days and tried 6.9±3.1 preventive medications. Overall, they used roughly 7.8±7.0 sprays (ie., 78 mg) per day and 11.6±8.9 days per month. Intranasal ketamine was reported as “very effective” in 49.1% and quality of life (QOL) was considered “much better” in 35.5%. However, 74.0% reported at least one adverse event (AE). In this retrospective study, IN ketamine can serve as an acute treatment for rCM by reducing headache intensity and improving QOL with relatively tolerable AEs. Most patients found IN ketamine effective and continued to use it despite these AEs. The study is limited by its single-center design and selection/recall biases. Well-designed prospective placebo-controlled trials are necessary to demonstrate the efficacy and safety of IN ketamine in patients with migraine. What is already known on this topic – Intravenous ketamine, although has been used for chronic pain and refractory headache, is limited to infusion settings. Intranasal ketamine, a more convenient alternative, has not been well-studied for refractory headache. What this study adds – This real-world study describes the usage pattern, effectiveness, and adverse event profiles of intranasal ketamine in patients with refractory chronic migraine. How this study might affect research, practice or policy – Intranasal ketamine is probably effective with minimal adverse events for refractory chronic migraine, but more well-designed studies are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A prospective study also found that intranasal ketamine effectively reduced headache intensity and improved quality of life in 169 participants with refractory chronic migraines [136]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A prospective study also found that intranasal ketamine effectively reduced headache intensity and improved quality of life in 169 participants with refractory chronic migraines [136]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [136]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The REDCap consortium: building an international community of software platform partners
Harris, P. A., Taylor, R., Minor, B. L., Elliott, V., Fernandez, M., O'Neal, L., McLeod, L., Delacqua, G., Delacqua, F., Kirby, J., et al. (2019) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2019.103208 · Cited by 24,013
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Ketamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385
Cohen, S. P., Bhatia, A., Buvanendran, A., Schwenk, E. S., Wasan, A. D., Hurley, R. W., Viscusi, E. R., Narouze, S., Davis, F. N., Ritchie, E. C., et al. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000808 · Cited by 350
Self-citationSacco, S., Braschinsky, M., Ducros, A., Lampl, C., Little, P., van den Brink, A. M., Pozo-Rosich, P., Reuter, U., de la Torre, E. R., Sanchez Del Rio, M., et al. (2020) · The Journal of Headache and Pain · doi:10.1186/s10194-020-01130-5 · Cited by 266
The role of ketamine in pain management
Visser, E., & Schug, S. A. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.06.021 · Cited by 256
Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine
Kaube, H., Herzog, J., Käufer, T., Dichgans, M., & Diener, H. C. (2000) · Neurology · doi:10.1212/wnl.55.1.139 · Cited by 212
A randomized controlled trial of intranasal ketamine in migraine with prolonged aura
Afridi, S. K., Giffin, N. J., Kaube, H., & Goadsby, P. J. (2013) · Neurology · doi:10.1212/wnl.0b013e3182824e66 · Cited by 162
Suman, J., Laube, B. L., & Dalby, R. N. (1999) · Pharmaceutical Research · doi:10.1023/a:1011933410898 · Cited by 140
Cited by
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Mechanistic intersections between migraine and major depressive disorder
Johnson, M., Filali, Y., Adegboyo, A., Eberle, M., Townsend, A., Hussien, Y., Marcinkiewcz, C. A., & Hultman, R. C. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-02097-x · Cited by 17
Glutamate as a Therapeutic Substrate in Migraine
Karsan, N., Alves, L. B., & Goadsby, P. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073023 · Cited by 17
Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management
Strand, N. H., Whitney, M. A., Johnson, B. W., Dunn, T., Attanti, S., Maloney, J. A., Misra, L., Gomez, D., Viswanath, O., Emami, E., et al. (2025) · Current Pain and Headache Reports · doi:10.1007/s11916-024-01353-0 · Cited by 15
Ibero-American consensus statement on migraine treatment
Laínez, J. M., Pradilla-Vesga, O. E., Irimia, P., Sobrino, F., Volcy, M., Kowaks, P., Rodríguez‐Leyva, I., Martín, F., Zavala, L. J., & Espinoza, A. R. (2024) · Neurology Perspectives · doi:10.1016/j.neurop.2024.100182 · Cited by 5
Metadata
- Authors
- Yuan, H., Natekar, A., Park, J. S., Lauritsen, C., Viscusi, E. R., & Marmura, M. J.
- Affiliations
- Thomas Jefferson University (US)
- OhioHealth (US)
- Rush University (US)
- Corresponding author
- Marmura, Michael J.
- Venue
- medRxiv
- Publisher
- openRxiv
- Published
- 2022-11-22
- OpenAlex
- W4309653137
- Cited by
- 1
- References
- 30
- Citations by year
- 2023: 1
- Type
- posted content
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Funders
- Amgen
- Eli Lilly and Company
- Teva Pharmaceutical Industries
- Upsher-Smith
- University of Cambridge
- National Institutes of Health
- Allergan
- Topics
- Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Keywords
- intranasal ketamine, refractory headache, acute migraine treatment, quality of life, adverse events, treatment effectiveness, outpatient care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real-world study of intranasal ketamine for use in patients with refractory chronic migraine. https://app.cochat.ai/papers/10.1101/2022.11.20.22282558
- The paper
- Yuan, H., Natekar, A., Park, J. S., Lauritsen, C., Viscusi, E. R., & Marmura, M. J. (2022). Real-world study of intranasal ketamine for use in patients with refractory chronic migraine. medRxiv. https://doi.org/10.1101/2022.11.20.22282558
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.